Vaccine Partnerships Strategic collaboration with Gates Foundation, NIH VRC, CEPI, and a public pharma partner signals strong interest in vaccine platforms and potential co-development or procurement opportunities for mRNA and other vaccine candidates.

Vaccines Access Recent CEPI financing and a focus on improving vaccine delivery and accessibility create a sales pathway for manufacturing support, formulation optimization, and regional distribution services in Africa and beyond.

Liposome Platform Liposomal antibacterial and infectious disease formulations offer opportunities to partner on drug delivery optimization, biodistribution profiling, and toxicity reduction services for tuberculosis and related pathogens.

Manufacturing Footprint Rwanda-based subsidiary for manufacturing and clinical trials, plus laboratories in Boston and San Francisco, suggest capacity for collaboration on clinical GMP manufacturing, tech transfer, and regional supply chain solutions.

Funding Momentum Recent $1.5M financing for vaccine access initiatives indicates investor appetite and potential for follow-on capital to scale partnerships, contract manufacturing, and joint development programs.